Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether the combination of axitinib and
nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal
melanoma that has not been treated before.
The researchers think that a combination of axitinib and nivolumab may help people with this
disease because both drugs target and block proteins that play a role in cancer cell survival
and growth. The researchers think the drugs may be more effective if given in combination
rather than on their own.